The COVID-19 Pilot Grant Program launched at the end of March in response to the Coronavirus pandemic. In a very short time, CTSI received an overwhelming amount of interest from the research community:
On Thursday, April 16, CTSI awarded $900,000 to 17 studies to address different aspects of the COVID-19 pandemic.
Funding for the projects was provided by the University’s Clinical and Translational Science Institute, the Office of the Provost, the Office of the Senior Vice Chancellor for Research, and the DSF Charitable Foundation, which contributed $350,000.
Please see below for the list of COVID-19 Pilot Grant Program awardees.
SARS-CoV-2 clinical and community serosurveillance, Principal Investigators (co-PIs) Paul Duprex, PhD, Anita McElroy, MD, PhD, and Alan Wells, MD, DMSc
Biomarkers for Predicting Viral Pneumonia Severity, Principal Investigator (PI) John Alcorn, PhD
Cellular Mechanisms of SARS-CoV-2 Infection, co-PIs Sally Wenzel, MD, and Xiuxia Zhou, PhD
Coronavirus and Lung Microbiome Interactions, PI Georgios Kitsios, MD, PhD
COVID-19 Neurologic Manifestations, PI Sherry Hsiang-Yi Chou, MD, MMSc
COVID-Insight Triage and Monitoring Tool, PI David Salcido, PhD, MPH
Determinants of COVID-19 clinical outcomes, co-PIs Christian Fernandez, PhD, Ernesto Marques, MD, PhD, Donald Burke, MD, and Philip Empey, PharmD, PhD
Generation of transgenic hACE2 knock-in mice, co-PIs Andrea Gambotto, MD, Lou Falo, MD, PhD, Mark Shlomchik, MD, PhD, and William Klimstra, PhD
Impact of Maternal COVID-19 Infection on Newborns, co-PIs Anne-Marie Rick, MD, MPH, and Judith Martin, MD
Lung-Targeting SARS-CoV-2 Therapeutic, PI Raymond Frizzell, PhD
Modeling Strategies for the COVID-19 Pandemic, PI Mark Roberts, MD
Pediatric Epidemiology SARS-CoV-2 antibody response, co-PIs Sarah Wheeler, PhD, Glenn Rapsinski, MD, PhD, and Megan Culler Freeman, MD, PhD
SARS-CoV-2 Cellular Imaging System, PI Zandrea Ambrose, PhD
SARS-CoV-2 Immune Escape Variants in Treatment, PI Jana Jacobs, PhD
SARS-CoV-2 Prevention Spray, Co-PIs Lisa Rohan, PhD, and Sravan Kumar Patel, PhD
Therapeutic nanobodies for SARS-CoV-2, PI Yi Shi, PhD
Therapy for COVID-19 Induced ARDS, PI Luis Ortiz, MD